Spoken Alpha
IONS
IONIS PHARMACEUTICALS INC
Overview
Ionis Pharmaceuticals designs RNA-targeted medicines to treat serious diseases. The company markets seven approved medicines for conditions including spinal muscular atrophy, amyotrophic lateral sclerosis, hereditary angioedema, and rare metabolic and neurological disorders, with revenue of $944 million in 2025.
IONIS PHARMACEUTICALS INC is a Healthcare company operating in Biotechnology with a $7.48B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-10-04.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2026Earnings2026-07-2918 Q&A exchanges
- Q1 FY2026Earnings2026-04-2913 Q&A exchanges
- Q4 FY2025Earnings2026-02-2511 Q&A exchanges
- Q3 FY2025Earnings2025-10-2921 Q&A exchanges
- Q2 FY2025Earnings2025-07-3015 Q&A exchanges
- Q1 FY2025Earnings2025-04-3011 Q&A exchanges
- Q4 FY2024Earnings2025-02-1914 Q&A exchanges
- Q3 FY2024Earnings2024-11-0628 Q&A exchanges
- Q2 FY2024Earnings2024-08-0116 Q&A exchanges
- Q1 FY2024Earnings2024-05-0714 Q&A exchanges
- Q4 FY2023Earnings2024-02-2124 Q&A exchanges
- Q3 FY2023Earnings2023-11-0228 Q&A exchanges
- Q2 FY2023Earnings2023-08-0917 Q&A exchanges
- Q1 FY2023Earnings2023-05-0324 Q&A exchanges
- Q4 FY2022Earnings2023-02-2220 Q&A exchanges
- Q3 FY2022Earnings2022-11-0916 Q&A exchanges
- Q2 FY2022Earnings2022-08-0934 Q&A exchanges
- Q1 FY2022Earnings2022-05-0418 Q&A exchanges
- Q4 FY2021Earnings2022-02-2420 Q&A exchanges
- Q3 FY2021Earnings2021-11-0317 Q&A exchanges
- Q2 FY2021Earnings2021-08-0419 Q&A exchanges
- Q1 FY2021Earnings2021-05-0529 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-03EPS— vs $-1.21—Rev— vs ——EODHD
- Q2 FY20262026-07-28EPS$-0.70 vs $-1.09+35.8%Rev$267.9M vs ——EODHD
- Q1 FY20262026-04-28EPS$-0.30 vs $-0.77+61.0%Rev$246.1M vs ——EODHD
- Q4 FY20252026-02-24EPS$-1.15 vs $-1.33+13.7%Rev$203.0M vs ——EODHD
- Q3 FY20252025-10-28EPS$-0.61 vs $-1.05+41.9%Rev$156.7M vs ——EODHD
- Q2 FY20252025-07-29EPS$0.85 vs $0.16+100.0%Rev$452.0M vs ——EODHD
- Q1 FY20252025-04-29EPS$-0.92 vs $-1.03+10.7%Rev$131.6M vs ——EODHD
- Q4 FY20242025-02-18EPS$-0.43 vs $-0.84+49.0%Rev$226.6M vs ——EODHD
- Q3 FY20242024-11-05EPS$-0.95 vs $-1.16+18.1%Rev$133.8M vs ——EODHD
- Q2 FY20242024-07-31EPS$-0.24 vs $-0.76+68.4%Rev$225.3M vs ——EODHD
- Q1 FY20242024-05-06EPS$-0.77 vs $-0.83+7.2%Rev$119.5M vs ——EODHD
- Q4 FY20232024-02-20EPS$-0.06 vs $-0.83+92.8%Rev$119.5M vs ——EODHD
- Q3 FY20232023-11-01EPS$-0.85 vs $-0.89+4.5%Rev$144.2M vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.41 vs $-0.70+41.4%Rev$188.4M vs ——EODHD
- Q1 FY20232023-05-02EPS$-0.68 vs $-0.76+10.5%Rev$130.5M vs ——EODHD
- Q4 FY20222023-02-21EPS$-1.36 vs $-0.92-47.8%Rev$151.9M vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.16 vs $-0.53+69.8%Rev$159.8M vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.56 vs $-0.47-19.1%Rev$133.8M vs ——EODHD
- Q1 FY20222022-05-03EPS$-0.27 vs $-0.52+48.1%Rev$141.9M vs ——EODHD
- Q4 FY20212022-02-23EPS$1.41 vs $0.28+100.0%Rev$440.0M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-1.21 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-28 | $-0.70 | $-1.09 | +35.8% | $267.9M | — | — | EODHD |
| Q1 FY2026 | 2026-04-28 | $-0.30 | $-0.77 | +61.0% | $246.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-1.15 | $-1.33 | +13.7% | $203.0M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.61 | $-1.05 | +41.9% | $156.7M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $0.85 | $0.16 | +100.0% | $452.0M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.92 | $-1.03 | +10.7% | $131.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $-0.43 | $-0.84 | +49.0% | $226.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.95 | $-1.16 | +18.1% | $133.8M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.24 | $-0.76 | +68.4% | $225.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.77 | $-0.83 | +7.2% | $119.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $-0.06 | $-0.83 | +92.8% | $119.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.85 | $-0.89 | +4.5% | $144.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.41 | $-0.70 | +41.4% | $188.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-0.68 | $-0.76 | +10.5% | $130.5M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-1.36 | $-0.92 | -47.8% | $151.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.16 | $-0.53 | +69.8% | $159.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.56 | $-0.47 | -19.1% | $133.8M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-0.27 | $-0.52 | +48.1% | $141.9M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $1.41 | $0.28 | +100.0% | $440.0M | — | — | EODHD |
Source: EODHD. IONS reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Brett P MoniaCEO6 yr 10 mo22 callsCurrent
- Elizabeth L HougenCFO6 yr 3 mo8 callsCurrent
- Holly B KordasiewiczEVP, Chief Development Officer11 mo1 callCurrent
- Joseph BaroldiEVP, Chief Business Officer4 yr 7 mono recorded callsCurrent
- Richard S. GearyEVP, Chief Development Officer4 yr 10 mo15 callsCurrent
- Patrick R O'NeilEVP CLO & General Counsel4 yr 10 mono recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IONS.
$ curl https://api.spokenalpha.com/v1/companies/IONSFAQ
Frequently asked about IONS
Where can I find IONIS PHARMACEUTICALS INC's (IONS) earnings call transcripts?
Spoken Alpha indexes IONS's earnings call transcripts at https://spokenalpha.com/companies/IONS. Each call links to attributed speakers and parsed analyst Q&A. IONIS PHARMACEUTICALS INC's own investor relations page is at https://ir.ionis.com/.
When was IONIS PHARMACEUTICALS INC's most recent earnings call?
IONIS PHARMACEUTICALS INC (IONS) held its most recent earnings call on 2026-07-29, covering fiscal Q2 2026.
What sector is IONS in?
IONIS PHARMACEUTICALS INC (IONS) operates in the Healthcare sector (Biotechnology industry).